scholarly journals Attitudes among dermatologists regarding non-melanoma skin cancer treatment options

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Luca Fania ◽  
Tonia Samela ◽  
Gaia Moretta ◽  
Francesco Ricci ◽  
Elena Dellambra ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Treatment Options ◽  
Locally Advanced ◽  
Central Italy ◽  
Therapeutic Approaches ◽  
Antibody Treatment ◽  
Skin Cancers ◽  
Melanoma Skin

AbstractNon-melanoma skin cancers include basal and squamous cell carcinoma. These tumors have become an important health issue for their high incidence and for the morbidity, especially if untreated for a long period. Over the last 20 years, therapeutic approaches for these tumours have been improved and tailored. In this survey we provided data from one hundred and ten Italian dermatologists regarding knowledge and attitude towards different therapeutic approaches on non-melanoma skin cancers. In our study, we observed that surgery and imiquimod 5% cream were the most used treatment by dermatologists for basal cell carcinoma, while, surgery was the most common treatment for cutaneous squamous cell carcinoma. Furthermore, we observed some differences regarding the prescribed therapies in the different Italian geographical areas (i.e., Mohs’ surgery and electrochemotherapy were more frequently used in Northern compared to Central and Southern Italy whereas immunotherapy was more used in Southern compared to Northern and Central Italy) and even considering the year of specialization of the dermatologists (i.e., immunotherapy with cemiplimab was prescribed mainly by dermatologists with 10–19 years of specialization). However, for locally advanced and metastatic forms of basal and squamous cell carcinoma, Hedgehog Pathway Inhibitors and anti- Programmed cell death protein antibody treatment, respectively, were used in line with the newest evolution of therapies regarding this topic. Considering the importance of skin cancers and its progressive increase in incidence, it is crucial to improve the knowledge of different therapeutic approaches among dermatologists.

scholarly journals Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma

2020 ◽  
Vol 27 (4) ◽  
Author(s):  
J. Claveau ◽  
J. Archambault ◽  
D.S. Ernst ◽  
C. Giacomantonio ◽  
J.J. Limacher ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Treatment Options ◽  
Locally Advanced ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Severe Toxicity ◽  
Curative Surgery ◽  
Skin Cancers ◽  
Clinical Benefits

Non-melanoma skin cancers are the most prevalent form of cancer, with cutaneous squamous cell carcinoma (cscc) being the 2nd most common type. Patients presenting with high-risk lesions associated with locally advanced or metastatic cscc face high rates of recurrence and mortality. Accurate staging and risk stratification for patients can be challenging because no system is universally accepted, and no Canadian guidelines currently exist.    Patients with advanced cscc are often deemed ineligible for either or both of curative surgery and radiation therapy (rt) and, until recently, were limited to off-label systemic cisplatin–fluorouracil or cetuximab therapy, which offers modest clinical benefits and potentially severe toxicity. A new systemic therapy, cemiplimab, has been approved for the treatment of locally advanced and metastatic cscc. In the present review, we provide recommendations for patient classification and staging based on current guidelines, direction for determining patient eligibility for surgery and rt, and an overview of the available systemic treatment options for advanced cscc and of the benefits of a multidisci­plinary approach to patient management.

scholarly journals A Case of Squamous Cell Carcinoma of Skin Subsequent to Subcutaneous Foreign Body

2016 ◽  
Vol 12 (1) ◽  
pp. 53-55
Author(s):  
P Anwar ◽  
S Mubashir ◽  
I Hassa ◽  
T Arif
Keyword(s):  
Squamous Cell Carcinoma ◽  
Foreign Body ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Foreign Bodies ◽  
Transposition Flap ◽  
Skin Cancers ◽  
Flap Closure ◽  
Melanoma Skin

Squamous cell carcinoma (SCC) of the skin is one of the most common non melanoma skin cancers (NMSC), along with basal cell carcinoma (BCC). Besides ultraviolet radiation, the role of exposure to industrial agents, ionizing radiation and areas of chronic inflammation is associated with the development of SCC. SCC may also be associated with foreign bodies. We report a rare case of cutaneous SCC in an elderly Kashmiri female, developing subsequent to subcutaneous non metallic foreign body, which was successfully excised with negative margins, and transposition flap closure. DOI: http://dx.doi.org/10.3126/njdvl.v12i1.10604 Nepal Journal of Dermatology, Venereology & Leprology Vol.12(1) 2014 pp.53-55

scholarly journals Complete Remission of Locally Advanced Penile Squamous Cell Carcinoma after Multimodality Treatment

Rare Tumors ◽  
2016 ◽  
Vol 8 (4) ◽  
pp. 191-193
Author(s):  
Yifan Meng ◽  
Helen Levey Bernie ◽  
Tzu-Hua Weng ◽  
Dean-An Ling ◽  
Edward M. Messing ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Complete Remission ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Clinical Decision Making ◽  
Treatment Options ◽  
Locally Advanced ◽  
Additional Treatment ◽  
Penile Squamous Cell Carcinoma

Treatment of locally advanced penile squamous cell carcinoma (pSCC) remains highly controversial secondary to disease rarity and lack of prospective randomized controlled trials. The current mainstays of care are multi-modality treatment with neoadjuvant chemotherapy and surgery. However, clinicians often have difficulty making recommendations for patients unable to tolerate chemotherapy or surgery due to scarcity of data to guide clinical decision-making. We report two cases of locally advanced pSCC that achieved complete remission after treatment with cisplatin-based neoadjuvant chemotherapy and surgery in one case, and concurrent cisplatin chemoradiation in a second, supporting the use of chemotherapy as part of first-line multimodal therapy. We also discuss additional treatment options for patients unable to tolerate traditional chemotherapy regimens.

Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective

2021 ◽  
Author(s):  
Kelly M Wilmas ◽  
Quoc-Bao Nguyen ◽  
Jigar Patel ◽  
Sirunya Silapunt ◽  
Michael R Migden
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Therapy ◽  
Antitumor Activity ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Treatment Options ◽  
Locally Advanced ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Durable Response ◽  
Alternative Approach

Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies, which carried marginal clinical benefit. The introduction of immunotherapy with anti-PD-1 antibodies resulted in alternative treatment options for advanced cutaneous squamous cell carcinoma with substantial antitumor activity, durable response and acceptable safety profile. The field of immunotherapeutics continues to expand with adjuvant, neoadjuvant and intralesional studies currently in progress. Herein, the authors discuss their approach for the treatment of advanced cutaneous squamous cell carcinoma from the perspective of a Mohs surgeon and a dermatologic oncologist.

scholarly journals Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma

2021 ◽  
Vol 23 (1) ◽  
pp. 94-98
Author(s):  
Anastasia V. Ignatova
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Checkpoint Inhibitors ◽  
Treatment Options ◽  
Locally Advanced ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Molecular Profile ◽  
New Information ◽  
New Treatment

Squamous cell carcinoma of the skin, or cutaneous squamous cell carcinoma (CSCC), is the second most frequent type of skin cancer, and its incidence continues to rise all over the world. Usually has a benign clinical behavior, but it can be presented as locally invasive and metastatic aggressive tumor with 2% mortality rate. Nowadays, new risk factors for have appeared, that form pharmacologically-induced CSCC after immunosuppressant drugs used for organ transplantation, or BRAF inhibitors used for melanoma. In recent years we have got a new information about the role of mutational burden, signaling pathways involved in CSCC development and new possibilities and molecules for targeted therapy. Better understanding of the immune system functioning and benefits of immunotherapy with immune checkpoint inhibitors (PD-1) for CSCC that has changed the therapeutic approach. According to recent clinical trials data, new treatment options with PD-1 inhibitors achieved a response rate of 50% for locally advanced CSCC and 47% for metastatic CSCC, including 16.1% complete remissions. This review focuses on the molecular profile, targeted therapies and immunotherapy for locally advanced and metastatic CSCC.

scholarly journals Climate change and its relationship with non-melanoma skin cancers

2018 ◽  
Vol 17 (12) ◽  
pp. 1913-1917 ◽  
Author(s):  
Rubén D. Piacentini ◽  
Lara Sofía Della Ceca ◽  
Adriana Ipiña
Keyword(s):  
Climate Change ◽  
Squamous Cell Carcinoma ◽  
Basal Cell Carcinoma ◽  
Ambient Temperature ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Basal Cell ◽  
Skin Cancers ◽  
Melanoma Skin

The increase in ambient temperature due to climate change is expected to affect the carcinogenicity of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).

scholarly journals Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma

2021 ◽  
Vol 22 (9) ◽  
pp. 4981
Author(s):  
Teresa Magnes ◽  
Sandro Wagner ◽  
Dominik Kiem ◽  
Lukas Weiss ◽  
Gabriel Rinnerthaler ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Checkpoint Inhibitors ◽  
Treatment Options ◽  
Locally Advanced ◽  
Neck Squamous Cell Carcinoma ◽  
Upper Aerodigestive Tract ◽  
Hpv Status

Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease arising from the mucosa of the upper aerodigestive tract. Despite multimodality treatments approximately half of all patients with locally advanced disease relapse and the prognosis of patients with recurrent or metastatic HNSCC is dismal. The introduction of checkpoint inhibitors improved the treatment options for these patients and pembrolizumab alone or in combination with a platinum and fluorouracil is now the standard of care for first-line therapy. However, approximately only one third of unselected patients respond to this combination and the response rate to checkpoint inhibitors alone is even lower. This shows that there is an urgent need to improve prognostication and prediction of treatment benefits in patients with HNSCC. In this review, we summarize the most relevant risk factors in the field and discuss their roles and limitations. The human papilloma virus (HPV) status for patients with oropharyngeal cancer and the combined positive score are the only biomarkers consistently used in clinical routine. Other factors, such as the tumor mutational burden and the immune microenvironment have been highly studied and are promising but need validation in prospective trials.

Sign in / Sign up

Export Citation Format

Share Document